Annual report pursuant to Section 13 and 15(d)

Fair Value Measurements (Tables)

v3.10.0.1
Fair Value Measurements (Tables)
12 Months Ended
Dec. 31, 2018
Fair Value Disclosures [Abstract]  
Financial Assets and Liabilities Carried at Fair Value on Recurring Basis

The following tables set forth the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as follows (in thousands):

 

 

Fair Value Measurements at December 31, 2018 Using

 

 

 

Quoted Prices in

Active Markets for

Identical Assets

 

 

Significant Other

Observable

Inputs

 

 

Significant

Unobservable

Inputs

 

 

 

 

 

 

 

(Level 1)

 

 

(Level 2)

 

 

(Level 3)

 

 

Total

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Long-term equity securities

 

$

 

 

$

 

 

$

392

 

 

$

392

 

 

 

 

Fair Value Measurements at December 31, 2017 Using

 

 

 

Quoted Prices in

Active Markets for

Identical Assets

 

 

Significant Other

Observable

Inputs

 

 

Significant

Unobservable

Inputs

 

 

 

 

 

 

 

(Level 1)

 

 

(Level 2)

 

 

(Level 3)

 

 

Total

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds (1)

 

$

34,907

 

 

$

 

 

$

 

 

$

34,907

 

 

(1) Included in cash and cash equivalents

Summary of Changes in Estimated Fair Value of Level 3 Financial Assets

The following table provides a summary of changes in the estimated fair value of the Company’s Level 3 financial assets for the year ended December 31, 2018 (in thousands):

 

Balance at December 31, 2017

 

$

 

Fair value of long-term equity securities at contract inception

 

 

955

 

Change in fair value

 

 

(563

)

Balance at December 31, 2018

 

$

392

 

Estimated Fair Value of Equity Securities Assumptions

The estimated fair value of the equity securities was calculated based on the following assumptions as of December 31, 2018 and the contract inception date of April 3, 2018:

 

 

 

December 31,

 

 

April 3,

 

 

 

2018

 

 

2018

 

Discount for lack of marketability

 

 

35

%

 

 

30

%

Estimated time to liquidity of shares

 

1.45 years

 

 

1.45 years

 

 

 

 

 

 

 

 

 

 

Scenario probabilities

 

 

 

 

 

 

 

 

Liquidation

 

 

20

%

 

 

65

%

Near-term sale

 

 

5

%

 

 

5

%

Near-term financing

 

 

75

%

 

 

30

%

Outstanding Long Term Debt Carrying Amount and Estimated Fair Value The carrying amount and the estimated fair value of the Company’s outstanding long-term debt at December 31, 2018 and December 31, 2017, are as follows (in thousands):

 

 

December 31, 2018

 

 

December 31, 2017

 

 

 

Carrying Amount

 

 

Fair Value

 

 

Carrying Amount

 

 

Fair Value

 

Novartis note

 

$

15,193

 

 

$

14,825

 

 

$

14,572

 

 

$

14,178

 

SVB Loan

 

 

7,286

 

 

 

7,281

 

 

 

 

 

 

 

Total

 

$

22,479

 

 

$

22,106

 

 

$

14,572

 

 

$

14,178